These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Respiratory syncytial virus seasonality, transmission zones, and implications for seasonal prevention strategy in China: a systematic analysis. Guo L; Deng S; Sun S; Wang X; Li Y Lancet Glob Health; 2024 Jun; 12(6):e1005-e1016. PubMed ID: 38670132 [TBL] [Abstract][Full Text] [Related]
23. Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants. Duppenthaler A; Gorgievski-Hrisoho M; Aebi C Swiss Med Wkly; 2001 Mar; 131(11-12):146-51. PubMed ID: 11416887 [TBL] [Abstract][Full Text] [Related]
24. A novel active respiratory syncytial virus surveillance system in the United States: variability in the local and regional incidence of infection. Boron ML; Edelman L; Groothuis JR; Malinoski FJ Pediatr Infect Dis J; 2008 Dec; 27(12):1095-8. PubMed ID: 18989237 [TBL] [Abstract][Full Text] [Related]
25. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Mitchell I; Tough S; Gillis L; Majaesic C Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279 [TBL] [Abstract][Full Text] [Related]
26. Variation in timing of respiratory syncytial virus outbreaks: lessons from national surveillance. Panozzo CA; Fowlkes AL; Anderson LJ Pediatr Infect Dis J; 2007 Nov; 26(11 Suppl):S41-5. PubMed ID: 18090199 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection. Gutfraind A; Galvani AP; Meyers LA JAMA Pediatr; 2015 Apr; 169(4):341-8. PubMed ID: 25706618 [TBL] [Abstract][Full Text] [Related]
28. Wastewater-based surveillance identifies start to the pediatric respiratory syncytial virus season in two cities in Ontario, Canada. Mercier E; Pisharody L; Guy F; Wan S; Hegazy N; D'Aoust PM; Kabir MP; Nguyen TB; Eid W; Harvey B; Rodenburg E; Rutherford C; Mackenzie AE; Willmore J; Hui C; Paes B; Delatolla R; Thampi N Front Public Health; 2023; 11():1261165. PubMed ID: 37829087 [TBL] [Abstract][Full Text] [Related]
29. Resurgence of Respiratory Syncytial Virus in Children: An Out-of-Season Epidemic in Portugal. Torres AR; Guiomar RG; Verdasca N; Melo A; Rodrigues AP; Acta Med Port; 2023 May; 36(5):343-352. PubMed ID: 36705636 [TBL] [Abstract][Full Text] [Related]
30. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease. Feltes TF; Sondheimer HM Expert Opin Biol Ther; 2007 Sep; 7(9):1471-80. PubMed ID: 17727335 [TBL] [Abstract][Full Text] [Related]
31. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009. Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095 [TBL] [Abstract][Full Text] [Related]
32. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports. Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338 [TBL] [Abstract][Full Text] [Related]
34. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. ; Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304 [TBL] [Abstract][Full Text] [Related]
35. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Robinson KA; Odelola OA; Saldanha I; McKoy N Cochrane Database Syst Rev; 2010 Feb; (2):CD007743. PubMed ID: 20166098 [TBL] [Abstract][Full Text] [Related]
36. Respiratory syncytial virus activity--United States, July 2011-January 2013. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2013 Mar; 62(8):141-4. PubMed ID: 23446512 [TBL] [Abstract][Full Text] [Related]
37. Association Between Updated Guideline-Based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections. Grindeland CJ; Mauriello CT; Leedahl DD; Richter LM; Meyer AC Pediatr Infect Dis J; 2016 Jul; 35(7):728-32. PubMed ID: 27078122 [TBL] [Abstract][Full Text] [Related]
38. Effect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation: A retrospective, observational study. Kamori A; Morooka Y; Yamamura K; Chong PF; Kuga N; Takahata Y; Sagawa K; Furuno K Medicine (Baltimore); 2021 Nov; 100(47):e27952. PubMed ID: 34964779 [TBL] [Abstract][Full Text] [Related]
39. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan. Diehl JL; Daw JR; Coley KC; Rayburg R J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844 [TBL] [Abstract][Full Text] [Related]
40. Optimization strategy to minimize wastage of palivizumab during the 2008 RSV season in São Paulo, Brazil. Weckx LY; Fernandes MM; Monteiro AI; Souza AR; Moraes-Pinto MI J Trop Pediatr; 2009 Oct; 55(5):341-2. PubMed ID: 19203985 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]